

Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.
You can purchase shares of Marker Therapeutics (NASDAQ:MRKR) through any online brokerage.
Other companies in Marker Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Marker Therapeutics has a consensus price target of $12.38.
The stock price for Marker Therapeutics (NASDAQ: MRKR) is $0.9361 last updated November 13, 2026 at 7:47 PM EST.
There are no upcoming dividends for Marker Therapeutics.
Marker Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Marker Therapeutics.
Marker Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor...